MedTrace Logo

Reversal of Ventricular Remodeling With Toprol-XL

NCT00038077 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2010-11-19

No results posted yet for this study

Summary

The purpose of this study is to determine whether treatment with Toprol-XL for 12 months in asymptomatic heart failure subjects will improve their heart structure and thus prevent the progression to symptomatic disease.

Conditions

  • Heart Failure, Congestive

Interventions

DRUG

Seloken ZOK/Toprol-XL

50 mg

DRUG

Seloken ZOK/Toprol-XL

200 mg

DRUG

Placebo

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-08-31
Primary Completion
2003-09-30
Completion
2003-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00038077 on ClinicalTrials.gov